PRKN and Parkinson disease: In addition, by inhibiting the excessive release of α-synuclein, which oligomerizes, aggregates, and deposits in the cytoplasm, Parkin SNO can be reduced, and cells can be protected from extracellular α-synuclein oligomer-induced toxicity, thus contributing to the development of new therapies for PD.